NCT02031276View on ClinicalTrials.gov

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

November 30, 2016

Conditions
Crohn Disease
Interventions
DRUG

risankizumab IV

risankizumab administered by IV infusion

DRUG

risankizumab SC

risankizumab administered by SC injection

DRUG

Placebo

Placebo for risankizumab administered by IV infusion

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY